"Favipiravir could be a potential treatment for COVID-19"- Sushrut Kulkarni
May 06, 2020 | Wednesday | Views
Sushrut Kulkarni, Executive Vice President – Global R&D, Glenmark Pharmaceuticals, Mumbai talks about the latest developments at Glenmark for fighting COVID-19
“After having successfully developed the API and the formulations through its in-house R&D team, Glenmark is all geared to immediately begin clinical trials on Favipiravir on COVID-19 patients in India. The clinical trial will let us know the efficacy of this molecule on COVID-19 patients. If the clinical trials are successful, Favipiravir could become a potential treatment for COVID-19 patients.”
- Sushrut Kulkarni, Executive Vice President – Global R&D, Glenmark Pharmaceuticals, Mumbai
